Although it is currently unclear whether inflammatory responses are a primary cause or a secondary effect in T2D progression, therapies targeting IL-1β have shown encouraging progress albeit diverse results in different clinical trials [19]–[26]. Here, IL1B is linked to type 2 diabetes mellitus.